Dr. Shore on the Rationale for the Phase 3 HERO Trial in Advanced Prostate Cancer

HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer - InterviewПодробнее

HERO phase III trial in advanced prostate cancerПодробнее

Phase 3 trial results suggest potential new treatment approach for prostate cancerПодробнее

Dr. Shore on Clinical Trial ChallengesПодробнее

Dr. Shore on the Management of Patients with Advanced Prostate CancerПодробнее

LISTEN: Phase 3 HERO TrialПодробнее

HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate CancerПодробнее

Dr. Shore on the Objective of the HERO Trial in Advanced Prostate CancerПодробнее

Dr. Shore on the Safety Profiles of Relugolix and Leuprolide Acetate in Prostate CancerПодробнее

Electronic pathology reporting and clinical trial matching for advanced prostate cancerПодробнее

Dr. Shore on Immunotherapy Targeting PSA and PSMA in Biochemically Recurrent Prostate CancerПодробнее

Treatment Updates for Advanced Prostate Cancer – 2023 ZERO Prostate Cancer SummitПодробнее

TOP TALK (EP 2) - Explore the PROG & EXP of Relugolix in the treatment of prostate cancer.Подробнее

Rationale of Phase III PCS5 trial of hypofractionated radiotherapy for prostate cancerПодробнее

Lecture on medical oncology - highlights on medical treatment of advanced PCaПодробнее

HERO: relugolix as an oral androgen-deprivation therapy in prostate cancerПодробнее

HERO: Relugolix versus leuprolide acetate for advanced prostate cancerПодробнее

Dr. Shore on the TERRAIN Trial for Prostate CancerПодробнее

Dr. Shore on the Potential Utility of Relugolix in Advanced Prostate CancerПодробнее